BRISC Deficiency Drives Heart Failure by Regulating β-Catenin K63 Ubiquitination

Hypertension. 2026 Mar 6. doi: 10.1161/HYPERTENSIONAHA.125.25727. Online ahead of print.ABSTRACTBACKGROUND: Adverse cardiac remodeling and dysfunction are hallmarks of hypertensive heart failure, yet molecular mechanisms remain incompletely understood. K63-linked deubiquitination has emerged as a cr

L Lu Liu

Frailty Index Offers Greater Discrimination Than Age for Optimal Blood Pressure Targets: A Pooled Analysis of Two Randomized Trials

Hypertension. 2026 Mar 6. doi: 10.1161/HYPERTENSIONAHA.125.26397. Online ahead of print.ABSTRACTBACKGROUND: Contemporary hypertension guidelines emphasize individualized blood pressure (BP) management, often incorporating age; yet chronological age alone may be insufficient to guide optimal treatmen

Y Yizhen Lyu

Body Weight-Related Differences in Adipokines and Inflammatory Markers Among Women with Systemic Lupus Erythematosus

J Inflamm Res. 2026 Feb 28;19:579501. doi: 10.2147/JIR.S579501. eCollection 2026.ABSTRACTBACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease marked by chronic inflammation and frequent metabolic disturbances. Understanding the influence of body weight and hydroxychloroquine on ad

L Lucas M Carvalho

PICO-based assessment and categorization of evidence for digital health interventions: an inductive framework development

Front Digit Health. 2026 Feb 18;8:1755598. doi: 10.3389/fdgth.2026.1755598. eCollection 2026.ABSTRACTBACKGROUND: Despite the increasing number of systematic reviews on digital health interventions (DHIs), clear and robust evidence remains elusive due to methodological shortcomings in formulating res

U Uwe Buddrus

Long-term mortality and cause of death in people with tuberculosis compared with matched controls with influenza or non-typhoid salmonellosis in Australia: a retrospective cohort study

BMJ Public Health. 2026 Mar 2;4(1):e001848. doi: 10.1136/bmjph-2024-001848. eCollection 2026.ABSTRACTINTRODUCTION: Tuberculosis (TB) patients are thought to experience excess long-term morbidity and mortality. However, the long-term mortality of people with TB has not been compared with other common

A Anthony Byrne

Infectious disease outcomes associated with inadequate housing and access to healthy living practices in Australia: a systematic review

BMJ Public Health. 2026 Feb 27;4(1):e003531. doi: 10.1136/bmjph-2025-003531. eCollection 2026.ABSTRACTOBJECTIVES: Inadequate housing and living conditions underpin significant health and wellbeing inequality in Australia, particularly for Indigenous people. This review aimed to define infectious dis

K Kate Summer

Lactylation, Crotonylation and Succinylation: Decoding Their Roles in the Progression of Cardiovascular Disease

Rev Cardiovasc Med. 2026 Feb 4;27(2):45696. doi: 10.31083/RCM45696. eCollection 2026 Feb.ABSTRACTCardiovascular diseases (CVDs), such as atherosclerosis, myocardial remodeling, myocardial ischemia-reperfusion (I/R) injury, heart failure, and oxidative stress, are among the greatest threats to human

X Xuchao Hu

The Associations of Anthropometric Indices With Stages and Mortality in Cardiovascular-Kidney-Metabolic Syndrome: Insights From NHANES

Rev Cardiovasc Med. 2026 Feb 25;27(2):46650. doi: 10.31083/RCM46650. eCollection 2026 Feb.ABSTRACTBACKGROUND: Cardiovascular-kidney-metabolic (CKM) syndrome embodies the interconnection between cardiovascular, renal, and metabolic disorders. Anthropometric indices reflect distinct aspects of obesity

M Ming Zhong

Unraveling Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities: Pathway Insights, Mechanisms, and Emerging Therapeutic Targets

Rev Cardiovasc Med. 2026 Feb 10;27(2):43846. doi: 10.31083/RCM43846. eCollection 2026 Feb.ABSTRACTImmune checkpoints are critical regulatory molecules in the immune system that maintain self-tolerance by preventing excessive immune activation against healthy tissues while being exploited by malignan

B Biqi Zhang

Drug-Coated Balloons Beyond In-Stent Restenosis

Rev Cardiovasc Med. 2026 Feb 25;27(2):45108. doi: 10.31083/RCM45108. eCollection 2026 Feb.ABSTRACTDrug-coated balloons (DCBs) are rapidly gaining prominence, owing to the associated expanding clinical applications and therapeutic potential in interventional cardiology. Moreover, a growing body of ev

R Rahul Gupta

Potential Similarity of Serum Cholesterol Multivariate Coefficients in the Prediction of Coronary Heart Disease Across Populations: A Review From the Seven Countries Study

Rev Cardiovasc Med. 2026 Feb 26;27(2):46488. doi: 10.31083/RCM46488. eCollection 2026 Feb.ABSTRACTThis study aimed to review the unique contribution of the Seven Countries Study (SCS) of cardiovascular diseases to the possible non-heterogeneity in multivariate coefficients of serum cholesterol in pr

A Alessandro Menotti

Evaluation of EuroSCORE II to Determine the Prognosis of Patients With Moderate-To-Severe Aortic Stenosis: A Long-Term Retrospective Study

Rev Cardiovasc Med. 2026 Feb 4;27(2):42757. doi: 10.31083/RCM42757. eCollection 2026 Feb.ABSTRACTBACKGROUND: Aortic stenosis (AS) is a prevalent heart valve disease; however, morbidity and mortality are significantly reduced by aortic valve replacement (AVR). The European System for Cardiac Operativ

X Xianzhen Cai

Prognostic Value of Estimated Glomerular Filtration Rate in Older Patients With Acute Coronary Syndrome

Rev Cardiovasc Med. 2026 Feb 11;27(2):45446. doi: 10.31083/RCM45446. eCollection 2026 Feb.ABSTRACTBACKGROUND: While the association between estimated glomerular filtration rate (eGFR) and cardiovascular disease has been well established in younger populations, the prognostic significance of this mar

Y Yifan Li

Lymphocyte-To-Monocyte Ratio is Partially Mediated in Age-Related Cardiovascular Mortality in HFpEF: Immunosenescence, Inflamm-Aging, and Longevity

Rev Cardiovasc Med. 2026 Feb 11;27(2):45403. doi: 10.31083/RCM45403. eCollection 2026 Feb.ABSTRACTBACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is recognized as an aging-related clinical syndrome with high mortality, from which systemic inflammation could represent a primary cul

X Xiaojie Cai

Statin-Mediated Modulation of Nrf2 Signaling: Mechanisms and Therapeutic Implications in Atherosclerosis

Rev Cardiovasc Med. 2026 Feb 10;27(2):46903. doi: 10.31083/RCM46903. eCollection 2026 Feb.ABSTRACTStatins are the cornerstone of lipid-lowering therapy and exert significant pleiotropic effects, including antioxidant and anti-inflammatory actions, which contribute to statin-mediated cardiovascular b

B Basheer Abdullah Marzoog

Association Between HAVOC Score and New-Onset Atrial Fibrillation in Patients With ST-Segment Elevation Myocardial Infarction

Rev Cardiovasc Med. 2026 Feb 25;27(2):47061. doi: 10.31083/RCM47061. eCollection 2026 Feb.ABSTRACTBACKGROUND: The HAVOC score is an emerging tool for estimating the risk of atrial fibrillation (AF), which has attracted growing interest. However, the use of the HAVOC score to predict in-hospital new-

S Shuang Zhou

The Extent and Phenotype of Coronary Artery Disease in Diabetes and Prediabetes: Insights From Imaging Studies and Potential Therapeutic Implications

Rev Cardiovasc Med. 2026 Feb 13;27(2):47550. doi: 10.31083/RCM47550. eCollection 2026 Feb.ABSTRACTType 2 diabetes mellitus (T2DM) is a complex metabolic disorder that is associated with a markedly increased risk of coronary artery disease (CAD) and cardiovascular (CV) mortality compared with the gen

F Filippo Luca Gurgoglione

Multi-Omics Mechanisms of Trimethylamine Oxide and Cardiovascular Disease: A Review

Rev Cardiovasc Med. 2026 Feb 4;27(2):44420. doi: 10.31083/RCM44420. eCollection 2026 Feb.ABSTRACTCardiovascular diseases (CVDs) rank among the most prevalent conditions globally, encompassing coronary heart disease, hypertension, cardiomyopathy, and heart failure. The global prevalence of CVD contin

H Huan Yu

Targeting Tumor Necrosis Factor-α Mitigates Glucose Fluctuation-Induced Aortic Valve Fibrosis: Insights From Diabetic Rat Models

Rev Cardiovasc Med. 2026 Feb 13;27(2):42804. doi: 10.31083/RCM42804. eCollection 2026 Feb.ABSTRACTBACKGROUND: Calcific aortic valve disease (CAVD) is a progressive condition characterized by inflammation and fibrous calcification remodeling, with aortic valve fibrosis (AVF) representing the associat

Y Yu-Jia Chen

The Impact of Dual Antiplatelet Therapy Guided by Platelet Function Testing on the Prognosis of Patients With Dual High-Risk Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Rev Cardiovasc Med. 2026 Feb 11;27(2):41544. doi: 10.31083/RCM41544. eCollection 2026 Feb.ABSTRACTBACKGROUND: To investigate the effect of dual antiplatelet therapy (DAPT) guided by platelet function testing (PFT) on the prognosis of patients with acute coronary syndrome (ACS) at a high risk for isc

M Mengjie Lei

Employment of the Ascending Aortic Volume as a Predictor of Adverse Outcomes in Patients With Bicuspid Aortic Valve Disease

Rev Cardiovasc Med. 2026 Feb 6;27(2):42793. doi: 10.31083/RCM42793. eCollection 2026 Feb.ABSTRACTBACKGROUND: A bicuspid aortic valve (BAV) is a common congenital heart disease. The primary treatment for this condition involves the surgical replacement of both the aortic valve and the ascending aorta

H Haowei Li

Proximal Anchoring Technique: A Novel Technique to Prevent Coronary Stent Longitudinal Deformation

Rev Cardiovasc Med. 2026 Feb 10;27(2):44250. doi: 10.31083/RCM44250. eCollection 2026 Feb.ABSTRACTBACKGROUND: Precise coronary stent implantation is crucial for ostial and partial bifurcation lesions during percutaneous coronary intervention (PCI). Conventional post-dilation coronary stent implantat

S Song Zhang

Coronary Microvascular Dysfunction in Cardiomyopathies: Insights on Clinical and Prognostic Roles

Rev Cardiovasc Med. 2026 Feb 26;27(2):46829. doi: 10.31083/RCM46829. eCollection 2026 Feb.ABSTRACTCoronary microvascular dysfunction (CMD) is a key driver of ischemia and prognosis across several non-ischemic cardiomyopathies. This review summarizes the main tools for diagnosing microvascular dysfun

F Federico Giacobbe

The Lipoprotein(a) Implementation Gap: Bridging Evidence and Clinical Practice

Rev Cardiovasc Med. 2026 Feb 25;27(2):47152. doi: 10.31083/RCM47152. eCollection 2026 Feb.ABSTRACTLipoprotein(a) [Lp(a)] represents one of cardiovascular medicine's most profound implementation gaps: a genetically determined risk factor affecting 1.5 billion people worldwide, yet historically underu

H Hyun Suk Yang